It is currently Fri Oct 31, 2014 7:09 pm

News News of Campath (Lemtrada, Alemtuzumab)

Site map of Campath (Lemtrada, Alemtuzumab) » Forum : Campath (Lemtrada, Alemtuzumab)

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Infusion related side effects/allergic reactions.

I finished my first lot of infusions Friday, today is Monday morning.

I am feeling pretty shite. I am tiered, itching, stinging, blotchy (comes and goes), feeling old ms symptoms. I know it is early days, and I think this is expected side effects, but I don't know.
One of the neurologists said it would be though, another one didn't expect it to be too bad.

How long can I expect to feel knocked off ...
Read more : Infusion related side effects/allergic reactions. | Views : 84 | Replies : 0


MS drugs Lemtrada and Aubagio launched in Ireland

Genzyme's plans to grow its multiple sclerosis business in Europe continued with the launch of two new treatments in the Republic of Ireland.

The company, which serves as the biotech arm of French pharma firm Sanofi, today launched the injectable Lemtrada (alemtuzumab) in the country just weeks after oral multiple sclerosis (MS) treatment Aubagio (teriflunomide) hit the market...... Read More - http://www.ms-uk.org/lemtrada
Read more : MS drugs Lemtrada and Aubagio launched in Ireland | Views : 366 | Replies : 3


SMC approves Lemtrada for RRMS within NHS Scotland

Scottish Medicines Consortium approves Lemtrada for RRMS within NHS Scotland

"Scotland has one of the highest rates of multiple sclerosis in the world, and the approval of Lemtrada in Scotland is an important step forward for people with active RRMS who remain in need of new treatment options. MS treatments have come a long way in the past twenty years and the availability of Lemtrada provides an opportunity for neurologists to offer a new therapy ...
Read more : SMC approves Lemtrada for RRMS within NHS Scotland | Views : 1788 | Replies : 0


US FDA accepts MS drug Lemtrada resubmission for review

The US Food and Drug Administration (FDA) has accepted for review the Genzyme's resubmission of supplemental Biologics License Application (sBLA) seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A six-month review period has been assigned for the Lemtrada sBLA. Genzyme expects FDA action on the sBLA in the fourth quarter...... Read More - http://www.ms-uk.org/lemtrada
Read more : US FDA accepts MS drug Lemtrada resubmission for review | Views : 1298 | Replies : 0


Alemtuzumab: Do the benefits outweigh the risks?

Alemtuzumab: Do the benefits outweigh the risks in treating multiple sclerosis? http://www.ms-uk.org/lemtrada
Read more : Alemtuzumab: Do the benefits outweigh the risks? | Views : 598 | Replies : 0


NHS patients to get new MS drug

- Scientists have spent 25 years developing treatment at Cambridge
- Alemtuzumab infusion is given in two short courses over two years
- Despite costing £56,000, NICE has ruled treatment is cost-effective......Read More - http://www.ms-uk.org/lemtrada
Read more : NHS patients to get new MS drug | Views : 578 | Replies : 0


Accelerated lymphocyte recovery after alemtuzumab........

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

ABSTRACT

Objective: To test the hypothesis that accelerated peripheral blood mononuclear cell recovery after alemtuzumab treatment of multiple sclerosis is associated with recurrent disease activity and to investigate the claim that CD4 counts greater than 388.5 × 106 cells/mL at 12 months can be used to identify patients who may benefit from further treatment..... Read More - http://www.ms-uk.org/lemtrada
Read more : Accelerated lymphocyte recovery after alemtuzumab........ | Views : 722 | Replies : 0


Lemtrada slows brain atrophy and reduces new MS lesions

- Consistent effects seen across key MRI measures of disease activity; Effects were sustained beyond two-year pivotal MS studies. <br><br>

- Approximately 80 percent of patients treated with Lemtrada did not receive a third course of treatment in the first year of the extension........ Read more - http://www.ms-uk.org/lemtrada
Read more : Lemtrada slows brain atrophy and reduces new MS lesions | Views : 628 | Replies : 0


MS drug Lemtrada to be resubmitted to FDA for approval

Nearly four months after the Food and Drug Administration rejected a multiple sclerosis drug developed by Genzyme, citing the clinical trial’s design and a risk of serious side effects, the Cambridge biotech said Monday that it will resubmit an application for approval to the agency..... Read More - http://www.ms-uk.org/lemtrada
Read more : MS drug Lemtrada to be resubmitted to FDA for approval | Views : 580 | Replies : 0


NICE says 'yes' to Genzyme's MS drug Lemtrada

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has recommended the use of French drug major Sanofi subsidiary Genzyme's multiple sclerosis drug Lemtrada (alemtuzumab).

NICE is appraising alemtuzumab as a treatment for adults with relapsing & remitting multiple sclerosis, a chronic and disabling neurological condition that, as it progresses, can have a substantial negative impact on a person&rsquo;s quality of life........ Read More - http://www.ms-uk.org/lemtrada
Read more : NICE says 'yes' to Genzyme's MS drug Lemtrada | Views : 493 | Replies : 0


 

Login  •  Register


Statistics

Total posts 221020 • Total topics 22917 • Total members 14474


Contact us | Terms of Service